These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32487513)

  • 1. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.
    Çınar OE; Sayınalp B; Aladağ Karakulak E; Avşar Karataş A; Velet M; İnkaya AÇ; Ersoy Ortaç NE; Öcal S; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe Oİ
    Transfus Apher Sci; 2020 Oct; 59(5):102821. PubMed ID: 32487513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.
    Figlerowicz M; Mania A; Lubarski K; Lewandowska Z; Służewski W; Derwich K; Wachowiak J; Mazur-Melewska K
    Transfus Apher Sci; 2020 Oct; 59(5):102866. PubMed ID: 32636116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.
    Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM
    Front Immunol; 2021; 12():633323. PubMed ID: 34790190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
    Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
    Front Immunol; 2021; 12():711915. PubMed ID: 34276706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure.
    Keitel V; Bode JG; Feldt T; Walker A; Müller L; Kunstein A; Klindt C; Killer A; Senff T; Timm J; Ostermann P; Damagnez M; Lübke N; Adams O; Schaal H; Antoch G; Neubert J; Albrecht P; Meuth S; Elben S; Mohring A; Fischer JC; Bölke E; Hoenig M; Schulz AS; Luedde T; Jensen B
    Front Immunol; 2021; 12():645989. PubMed ID: 34012436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-SARS-CoV-2 hyperimmune plasma workflow.
    Annamaria P; Eugenia Q; Paolo S
    Transfus Apher Sci; 2020 Oct; 59(5):102850. PubMed ID: 32540345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.
    Yılmaz S; Ertuğrul Örüç N; Özcebe Oİ; Azap A; Çetin AT; Yenicesu İ; Öztürk A; Gündüz M; Tekin A
    Transfus Apher Sci; 2020 Oct; 59(5):102846. PubMed ID: 32593519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies.
    Li Y; Liu S; Zhang S; Ju Q; Zhang S; Yang Y; Wang H
    Transfus Apher Sci; 2020 Oct; 59(5):102839. PubMed ID: 32561113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India.
    Bansal N; Raturi M; Bansal Y
    Transfus Clin Biol; 2021 Aug; 28(3):296-298. PubMed ID: 34102319
    [No Abstract]   [Full Text] [Related]  

  • 11. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy.
    Bošnjak B; Odak I; Ritter C; Stahl K; Graalmann T; Steinbrück L; Blasczyk R; Falk CS; Schulz TF; Wedemeyer HH; Cornberg M; Ganser A; Förster R; Koenecke C
    Front Immunol; 2021; 12():721738. PubMed ID: 34456929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
    Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Google Trends demonstrate public interest in COVID-19 convalescent plasma therapy.
    Adkins BD; Booth GS
    J Clin Apher; 2021 Jun; 36(3):492-493. PubMed ID: 33340373
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.
    Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y
    Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis.
    Zhang LL; Liu Y; Guo YG; Chang J; Gao B; Li ZZ; Geng W; Hu P; Song B; Zhang X; Wan CC
    Turk J Haematol; 2021 Feb; 18(1):74-76. PubMed ID: 32988811
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report.
    Cantore I; Valente P
    Transfus Apher Sci; 2020 Oct; 59(5):102848. PubMed ID: 32888822
    [No Abstract]   [Full Text] [Related]  

  • 20. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.
    Vazquez SE; Bastard P; Kelly K; Gervais A; Norris PJ; Dumont LJ; Casanova JL; Anderson MS; DeRisi JL
    J Clin Immunol; 2021 Aug; 41(6):1169-1171. PubMed ID: 34009544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.